Efficacy and safety of camrelizumab-based regimens in advanced squamous cell carcinoma patients: a prospective multicenter study
Camrelizumab shows satisfactory efficacy and safety in advanced esophageal cancer patients, and the camrelizumab combination regimens seem to bring prolonged PFS than its monotherapy. The real-world design reflects routine clinical practice, supporting the generalizability of these findings. However, potential confounders may exist and the broad range of follow-up durations may contribute to variability in survival data. Therefore, our results should be interpreted cautiously.
Authors
- Wenxia Deng (ORCID: https://orcid.org/0009-0007-9835-4729)
- G. Sun
- Tai Ma (ORCID: https://orcid.org/0000-0003-0911-850X)
- Xinglai Guo
- Wanren Peng
- Hong Qian (ORCID: https://orcid.org/0000-0003-1455-1893)
- Chenghui Li (ORCID: https://orcid.org/0000-0002-5884-2265)
- Zhongxian Zheng
- Dong Qian
- Zhiyong Wei
- Gang Wang
- Shaojin Zhu
- Xiangde Jiang
- Zishu Wang
- Dong Zhao
- Liming Xia
- Jie Wei
- Weijia Jiang
- Xinzhong Li
- Genhe Wang
- Yifu He
Institutions
- Wannan Medical College (CN)
- Anhui Medical University (CN)
- Anhui University of Traditional Chinese Medicine (CN)
- Huangshan University (CN)
- Chizhou University (CN)
- Huaibei Mining (China) (CN)
- Huaian First People’s Hospital (CN)
- The People's Hospital Tongling (CN)
- Bozhou People's Hospital (CN)
- Fuyang Maternity and Child Health Care Hospital (CN)
- Anhui Provincial Hospital (CN)
- Anqing City Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Cixian People's Hospital (CN)
- Anyang Tumor Hospital (CN)
- First People's Hospital of Jingzhou (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-19
- DOI
- https://doi.org/10.3389/fphar.2026.1767096
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00